{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T23:53:42Z","timestamp":1768434822025,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T00:00:00Z","timestamp":1607299200000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>To determine if extended chemotherapy improves survival outcomes in patients with platinum-sensitive relapsed epithelial ovarian cancer (EOC) who have residual disease after six cycles of second-line chemotherapy.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>In this study, 135 EOC patients who experienced platinum-sensitive recurrence after primary treatment between 2008 and 2018, and had a residual tumor \u22650.5\u2009cm (detected on CT scans) after completing six cycles of second-line, platinum-based chemotherapy, were retrospectively reviewed. Based on the number of main therapy cycles (second-line chemotherapy), we divided patients into an extended group (&gt;6\u2009cycles, <jats:italic>n<\/jats:italic>\u2009=\u200952) or a standard group (6\u2009cycles, <jats:italic>n<\/jats:italic>\u2009=\u200983) and compared patient characteristics and survival outcomes between these groups.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The extended group had a shorter platinum-free interval after primary treatment than the standard group (median, 11.0 vs. 13.1\u2009months; <jats:italic>P<\/jats:italic>\u2009=\u20090.018). Secondary debulking surgery was less frequently performed in the standard group (1.9% vs. 19.3%; <jats:italic>P<\/jats:italic>\u2009=\u20090.003). After six chemotherapy cycles, the extended and standard groups showed similar serum CA-125 levels (<jats:italic>P<\/jats:italic>\u2009=\u20090.122) and residual tumor sizes (<jats:italic>P<\/jats:italic>\u2009=\u20090.232). There was no difference in overall survival (OS) between the groups (<jats:italic>P<\/jats:italic>\u2009=\u20090.382), although the extended group had significantly worse progression-free survival (PFS) than the standard group (median, 13.9 vs. 15.1\u2009months; <jats:italic>P<\/jats:italic>\u2009=\u20090.012). Multivariate analyses revealed that platinum-free interval was an independent prognostic factor for PFS and OS, but extended chemotherapy was not (PFS: HR, 1.25; 95% CI, 0.84\u20131.85; <jats:italic>P<\/jats:italic>\u2009=\u20090.279; and OS: HR, 1.36; 95% CI, 0.72\u20132.56; <jats:italic>P<\/jats:italic>\u2009=\u20090.342). We observed consistent results in the subset of patients who did not undergo secondary debulking surgery.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>More than six cycles of platinum-based chemotherapy might not improve survival outcomes in patients with platinum-sensitive recurrent EOC who had a residual tumor \u22650.5\u2009cm after six cycles of second-line chemotherapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-020-07658-8","type":"journal-article","created":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T10:05:56Z","timestamp":1607335556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Survival impact of extended cycles of second-line chemotherapy in platinum-sensitive relapsed ovarian cancer patients with residual tumor after six cycles"],"prefix":"10.1186","volume":"20","author":[{"given":"Se Ik","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo Yeon","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Seung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kidong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Hoon","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Hong","family":"No","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Weon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong Beom","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noh Hyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Sang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Hoon","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,7]]},"reference":[{"key":"7658_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"7658_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7\u201334.","journal-title":"CA Cancer J Clin"},{"key":"7658_CR3","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc1123","volume":"3","author":"R Agarwal","year":"2003","unstructured":"Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3:502\u201316.","journal-title":"Nat Rev Cancer"},{"key":"7658_CR4","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/IGC.0b013e31821bb8aa","volume":"21","author":"M Friedlander","year":"2011","unstructured":"Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, et al. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer. 2011;21:771\u20135.","journal-title":"Int J Gynecol Cancer"},{"key":"7658_CR5","volume-title":"Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer, Version 1","author":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology","year":"2020","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer, Version 1. 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf. Accessed 30 Apr 2020."},{"key":"7658_CR6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ygyno.2009.10.073","volume":"116","author":"JK Chan","year":"2010","unstructured":"Chan JK, Tian C, Fleming GF, Monk BJ, Herzog TJ, Kapp DS, et al. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a gynecologic oncology group study. Gynecol Oncol. 2010;116:301\u20136.","journal-title":"Gynecol Oncol"},{"key":"7658_CR7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ygyno.2009.04.012","volume":"114","author":"M Markman","year":"2009","unstructured":"Markman M, Liu PY, Moon J, Monk BJ, Copeland L, Wilczynski S, et al. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg\/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a southwest oncology group and gynecologic oncology group phase 3 trial. Gynecol Oncol. 2009;114:195\u20138.","journal-title":"Gynecol Oncol"},{"key":"7658_CR8","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/jjco\/hyn034","volume":"38","author":"HS Kim","year":"2008","unstructured":"Kim HS, Park NH, Chung HH, Kim JW, Song YS, Kang SB. Are three additional cycles of chemotherapy useful in patients with advanced-stage epithelial ovarian cancer after a complete response to six cycles of intravenous adjuvant paclitaxel and carboplatin? Jpn J Clin Oncol. 2008;38:445\u201350.","journal-title":"Jpn J Clin Oncol"},{"key":"7658_CR9","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","volume":"18","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG oncology\/gynecologic oncology group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:779\u201391.","journal-title":"Lancet Oncol"},{"key":"7658_CR10","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039\u201345.","journal-title":"J Clin Oncol"},{"key":"7658_CR11","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","volume":"28","author":"E Pujade-Lauraine","year":"2010","unstructured":"Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28:3323\u20139.","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"7658_CR12","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1111\/IGC.0b013e3181c14007","volume":"19","author":"P Sabbatini","year":"2009","unstructured":"Sabbatini P. Consolidation therapy in ovarian cancer: a clinical update. Int J Gynecol Cancer. 2009;19(Suppl 2):S35\u20139.","journal-title":"Int J Gynecol Cancer"},{"key":"7658_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/1758834010361333","volume":"2","author":"M Cristea","year":"2010","unstructured":"Cristea M, Han E, Salmon L, Morgan RJ. Practical considerations in ovarian cancer chemotherapy. Ther Adv Med Oncol. 2010;2:175\u201387.","journal-title":"Ther Adv Med Oncol"},{"key":"7658_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"7658_CR15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324.","journal-title":"Genet Med"},{"key":"7658_CR16","first-page":"3551","volume":"21","author":"V Mobus","year":"2001","unstructured":"Mobus V, Pfaff PN, Volm T, Kreienberg R, Kaubitzsch S. Long time therapy with topotecan in patients with recurrence of ovarian carcinoma. Anticancer Res. 2001;21:3551\u20136.","journal-title":"Anticancer Res"},{"key":"7658_CR17","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1158\/0008-5472.CAN-04-3931","volume":"65","author":"SA Bapat","year":"2005","unstructured":"Bapat SA, Mali AM, Koppikar CB, Kurrey NK. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 2005;65:3025\u20139.","journal-title":"Cancer Res"},{"key":"7658_CR18","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1007\/s00018-010-0420-9","volume":"67","author":"MF Shi","year":"2010","unstructured":"Shi MF, Jiao J, Lu WG, Ye F, Ma D, Dong QG, et al. Identification of cancer stem cell-like cells from human epithelial ovarian carcinoma cell line. Cell Mol Life Sci. 2010;67:3915\u201325.","journal-title":"Cell Mol Life Sci"},{"key":"7658_CR19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2174\/138161206775201956","volume":"12","author":"F Michor","year":"2006","unstructured":"Michor F, Nowak MA, Iwasa Y. Evolution of resistance to cancer therapy. Curr Pharm Des. 2006;12:261\u201371.","journal-title":"Curr Pharm Des"},{"key":"7658_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jtbi.2014.02.025","volume":"355","author":"J Foo","year":"2014","unstructured":"Foo J, Michor F. Evolution of acquired resistance to anti-cancer therapy. J Theor Biol. 2014;355:10\u201320.","journal-title":"J Theor Biol"},{"key":"7658_CR21","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/cdd.2008.20","volume":"15","author":"L Vermeulen","year":"2008","unstructured":"Vermeulen L, Sprick MR, Kemper K, Stassi G, Medema JP. Cancer stem cells--old concepts, new insights. Cell Death Differ. 2008;15:947\u201358.","journal-title":"Cell Death Differ"},{"key":"7658_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc1590","volume":"5","author":"M Dean","year":"2005","unstructured":"Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275\u201384.","journal-title":"Nat Rev Cancer"},{"key":"7658_CR23","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.3390\/ijms18122574","volume":"18","author":"M Prieto-Vila","year":"2017","unstructured":"Prieto-Vila M, Takahashi RU, Usuba W, Kohama I, Ochiya T. Drug Resistance Driven by Cancer Stem Cells and Their Niche. Int J Mol Sci. 2017;18:2574.","journal-title":"Int J Mol Sci"},{"key":"7658_CR24","doi-asserted-by":"publisher","first-page":"396076","DOI":"10.1155\/2011\/396076","volume":"2011","author":"N Moore","year":"2011","unstructured":"Moore N, Lyle S. Quiescent, slow-cycling stem cell populations in cancer: a review of the evidence and discussion of significance. J Oncol. 2011;2011:396076.","journal-title":"J Oncol"},{"issue":"suppl","key":"7658_CR25","doi-asserted-by":"publisher","first-page":"abstr5501","DOI":"10.1200\/JCO.2017.35.15_suppl.5501","volume":"35","author":"A Du Bois","year":"2017","unstructured":"Du Bois A, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, et al. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20. J Clin Oncol. 2017;35(suppl):abstr5501.","journal-title":"J Clin Oncol"},{"issue":"20","key":"7658_CR26","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","volume":"381","author":"RL Coleman","year":"2019","unstructured":"Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, et al. Secondary surgical Cytoreduction for recurrent ovarian Cancer. N Engl J Med. 2019;381(20):1929\u201339.","journal-title":"N Engl J Med"},{"key":"7658_CR27","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274\u201384.","journal-title":"Lancet Oncol."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07658-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-07658-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07658-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T10:17:59Z","timestamp":1607336279000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07658-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7658"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07658-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"10 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective cohort study was conducted after approval from the Institutional Review Boards of Seoul National University Hospital (No. J-2004-002-1114) and Seoul National University Bundang Hospital (No. B-2004-607-103). This study was performed in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1199"}}